Cardiac Dimensions is set to present the 12-month follow-up results of Carillon Mitral Contour System Titan trial at the European Society of Cardiology 2010 Congress (ESC) on 29 August 2010 in Stockholm.

The Carillon Mitral Contour System is a non-surgical, minimally invasive device designed to repair the mitral valve in the patients and reduce FMR and it combines an implantable device and a percutaneous delivery system.

The trial protocol evaluated the clinical impact of coronary sinus-based percutaneous mitral annuloplasty in symptomatic patients with both ischemic and non-ischemic dilated cardiomyopathy, at least moderate FMR, and stable medical therapy.

Cardiac Dimensions said that the data will allow for a comparison between the implanted and control groups, an assessment of whether reverse remodeling is associated with FMR reduction, and an analysis of the durability of this percutaneous repair technique.

Cardiac Dimensions CEO Rick Stewart said that the firm is confident that the long-term results of this latest trial of Carillon device will highlight the efficacy and durability of the mitral valve repair treatment.

“We are very grateful to our group of clinicians who are working with us to bring hope to the literally millions of heart failure patients suffering from FMR who currently have very few options. We look forward to executing European commercialization of this therapy and pushing forward with the U.S. investigational plan,” Stewart said.

Cardiac Dimensions is a provider of minimally invasive cardiovascular devices for the treatment of mitral valve disease.